Expedia price target raised to $351 from $322 at UBS
UBS raised its Expedia (EXPE) price target to $351 from $322 and kept a Neutral rating, citing Expedia’s strong Q2. The company reported gross bookings up 12%, revenue up 14%, and adjusted EBITDA up 23% to $1.12B, with U.S. demand and B2B momentum offsetting European softness.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the sell-side PT increase paired with a maintained Neutral stance, which can nudge sentiment but is not a fresh fundamental catalyst like guidance or a new earnings print.
Market read
This is a moderate sentiment update for EXPE tied to Q2 operating momentum, but the Neutral rating suggests limited conviction.
What to watch
European softness is explicitly noted; traders may discount the PT raise if they expect macro or FX headwinds to persist.
Background
The piece summarizes a UBS research note following Expedia’s Q2 performance, focusing on bookings growth, revenue growth, and adjusted EBITDA improvement.
Ticker impact
UBS raised its Expedia price target to $351 from $322 and kept a Neutral rating after citing strong Q2 bookings, revenue, and EBITDA.
Modest upside bias, with follow-through dependent on broader sell-side revisions.
The article provides a specific PT change and cites Q2 operating momentum (bookings, revenue, adjusted EBITDA) offset by European softness, but it is still an analyst note rather than a new company disclosure.
Market effects
Supports the view that travel demand and B2B momentum are improving, but European softness remains a counterweight.
Highlights a split between strong U.S. demand and weaker Europe, which can influence regional travel sentiment.
Limited spillover beyond the lodging/travel booking complex unless it triggers broader analyst consensus changes.
Counterpoint
A Neutral rating with a PT increase can reflect valuation upside without a fundamental rerating, limiting sustained momentum.
Key entities
- companyExpedia
Subject of the UBS price-target raise to $351 from $322, with a Neutral rating maintained.
- analyst_firmUBS
Issued the price-target change and provided the thesis citing Q2 strength and European softness.
